Sunday, March 23, 2014 5:21:39 PM
- Duke University’s Duke Clinical Research Institute, (DCRI) to conduct the Phase 3 trial of the Company’s newly acquired compound, levosimendan
- The United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan
- OXBT has been notified recently by the U.S. Food and Drug Administration (the “FDA”) that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte®.
- ongoing clinical trial in traumatic brain injury (TBI) is a double-blind, placebo–controlled, dose-escalation study.
- the Company received net proceeds of approximately $55.0 million
- New Management - new company guidance - Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics
Past is past and the future is bright, for everyone his own opinion but somebody would say all the above are lies and fluffy grams.
Time will tell and some will be right and some will be wrong.
Recent TENX News
- Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Tenax Therapeutics to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 • GlobeNewswire Inc. • 02/29/2024 02:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/26/2024 09:31:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:01:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:33:49 PM
- Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/16/2024 04:28:52 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/16/2024 12:36:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:46:29 PM
- Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering • GlobeNewswire Inc. • 02/08/2024 01:16:41 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:17 AM
- Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 02/08/2024 01:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:56:32 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM